■ Big Tech & AI Initiatives
Apple (AAPL) & Alphabet (GOOGL)
AI Alliance: Wedbush views the Apple-Gemini partnership as a major positive for both. Apple will use Gemini for Siri and other AI features, validating Alphabet's foundation model and accelerating Apple's post-2026 AI strategy. (Rating: Outperform / PT: $350)
Microsoft (MSFT): Goldman Sachs raised its target to $655, citing Microsoft's diversified AI strategy that allows it to win across multiple paths in the ecosystem.
Meta Platforms (META): Launched "Meta Compute," a new initiative to expand AI infrastructure to tens (and eventually hundreds) of gigawatts.
Amazon (AMZN): Partnered with Aumovio to build software for Aurora Innovation's autonomous trucks, with mass production expected by 2027.
■ Semiconductors & Tech Infrastructure
Micron Technology (MU)
Unprecedented Targets: Links surged its target to $550 (from $325), and BofA raised it to $400. Analysts expect massive investment to meet AI inference demand, shifting the valuation focus to sustainable earnings power.
Intel (INTC) & AMD (AMD): KeyBanc upgraded both to Overweight, citing the memory supercycle and data center demand.
Applied Materials (AMAT): Susquehanna issued a Positive outlook, expecting WFE spending to hit $150B annually.
TSMC (TSM): Analysts remain positive but cautious about the upcoming revenue guidance (expected 25-30%).
Reddit (RDDT): Evercore initiated coverage at Outperform ($320), projecting 30-40% revenue growth over 3 years.
■ Financials & Earnings Reports
JPMorgan (JPM): Q4 EPS ($5.23) and Revenue ($46.77B) beat estimates. Eyes are on CEO Jamie Dimon’s reaction to proposed credit card interest rate caps.
BNY Mellon (BK): Record AUC of $59.3T (+14% YoY). Raised mid-term ROTE goal to 28%.
BlackRock (BLK): Cutting 1% of global staff (250 employees) to reallocate resources toward private credit and infrastructure (GIP, HPS).
Delta Air Lines (DAL): Q4 EPS ($1.55) beat estimates, but revenue ($14.61B) slightly missed.
■ Healthcare & Biotech
Eli Lilly (LLY)
Approval Watch: Its oral weight-loss drug Orforglipron is expected to be approved this quarter.
M&A Rumor: Reportedly considering a $17.5B acquisition of French biotech Abivax (ABVX) for its ulcerative colitis pipeline.
Travere (TVTX): FDA requested additional data on Filspari, creating uncertainty for its FSGS indication approval.
Moderna (MRNA): Forecasts 10% revenue growth in 2026 and filed for flu vaccine approval in major markets.
■ Energy, Materials & Consumer
Lithium Sector (ALB, LAR, LAC)
Supply Deficit: Scotiabank upgraded the sector, forecasting a 14% CAGR in lithium demand through 2030.
Albemarle (ALB): Upgraded to Outperform ($200).
Lithium Argentina (LAR): Upgraded to Outperform ($7.75).
Vistra (VST): BMO raised the target to $244 following the 2.6GW nuclear deal with Meta.
L3Harris (LHX): DoD investing $1B in its missile segment; plans to spin off the unit in H2 2026.
Comcast (CMCSA): BofA upgraded to Buy ($37), noting undervalued assets post-cable spin-off.
Nike (NKE): Jefferies set a $110 target, citing its 15-year low valuation and turnaround progress.
Rivian (RIVN): Wolfe Research downgraded to Sell ($16), citing a lack of near-term catalysts compared to Tesla.
